Literature DB >> 16926135

AML1/Runx1 as a versatile regulator of hematopoiesis: regulation of its function and a role in adult hematopoiesis.

Mineo Kurokawa1.   

Abstract

AML1/Runx1, originally identified as a gene located at the breakpoint of the t(8;21) translocation, encodes a transcription factor that is widely expressed in multiple hematopoietic lineages and that regulates the expression of a variety of hematopoietic genes. Numerous studies have shown that AML1 is a critical regulator of hematopoietic development. In addition, AML1 is a frequent target for chromosomal translocation in human leukemia. The activity of AML1 can be modulated by various types of posttranslational modification, including phosphorylation and acetylation. Phosphorylation by extracellular signal-regulated kinase (ERK) is one of the mechanisms that dictate whether AML1 acts as either a transcriptional repressor or an activator of gene expression. Recently, a physiological role for AML1 in adult hematopoiesis was revealed by conditional gene targeting in mice. Remarkably, adult hematopoietic progenitors are maintained even in the absence of AML1, in stark contrast to the total disruption of definitive hematopoiesis during embryogenesis. AML1 is, however, critical for megakaryopoiesis and plays an important role in T-cell and B-cell development in adult mice. Recent analyses engineered to recreate hematopoiesis in vitro revealed that the transcriptional activity of AML1 is closely related with the potential of AML1 to generate hematopoietic cells and support thymocyte development.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16926135     DOI: 10.1532/IJH97.06070

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  43 in total

1.  Differential requirements for Runx proteins in CD4 repression and epigenetic silencing during T lymphocyte development.

Authors:  Ichiro Taniuchi; Motomi Osato; Takeshi Egawa; Mary Jean Sunshine; Suk Chul Bae; Toshihisa Komori; Yoshiaki Ito; Dan R Littman
Journal:  Cell       Date:  2002-11-27       Impact factor: 41.582

Review 2.  Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer.

Authors:  Saverio Minucci; Pier Giuseppe Pelicci
Journal:  Nat Rev Cancer       Date:  2006-01       Impact factor: 60.716

3.  Shared and distinct roles mediated through C-terminal subdomains of acute myeloid leukemia/Runt-related transcription factor molecules in murine development.

Authors:  Yoko Fukushima-Nakase; Yoshinori Naoe; Ichiro Taniuchi; Hajime Hosoi; Tohru Sugimoto; Tsukasa Okuda
Journal:  Blood       Date:  2005-02-15       Impact factor: 22.113

4.  In vitro expansion of murine multipotential hematopoietic progenitors from the embryonic aorta-gonad-mesonephros region.

Authors:  Y Mukouyama; T Hara; M Xu; K Tamura; P J Donovan; H Kim; H Kogo; K Tsuji; T Nakahata; A Miyajima
Journal:  Immunity       Date:  1998-01       Impact factor: 31.745

5.  VWRPY motif-dependent and -independent roles of AML1/Runx1 transcription factor in murine hematopoietic development.

Authors:  Motohiro Nishimura; Yoko Fukushima-Nakase; Yasuko Fujita; Mitsushige Nakao; Shogo Toda; Nobuo Kitamura; Tatsuo Abe; Tsukasa Okuda
Journal:  Blood       Date:  2003-09-22       Impact factor: 22.113

6.  The corepressor mSin3A regulates phosphorylation-induced activation, intranuclear location, and stability of AML1.

Authors:  Yoichi Imai; Mineo Kurokawa; Yuko Yamaguchi; Koji Izutsu; Eriko Nitta; Kinuko Mitani; Masanobu Satake; Tetsuo Noda; Yoshiaki Ito; Hisamaru Hirai
Journal:  Mol Cell Biol       Date:  2004-02       Impact factor: 4.272

7.  AML1 is functionally regulated through p300-mediated acetylation on specific lysine residues.

Authors:  Yuko Yamaguchi; Mineo Kurokawa; Yoichi Imai; Koji Izutsu; Takashi Asai; Motoshi Ichikawa; Go Yamamoto; Eriko Nitta; Tetsuya Yamagata; Kazuki Sasaki; Kinuko Mitani; Seishi Ogawa; Shigeru Chiba; Hisamaru Hirai
Journal:  J Biol Chem       Date:  2004-01-29       Impact factor: 5.157

8.  AML-1 is required for megakaryocytic maturation and lymphocytic differentiation, but not for maintenance of hematopoietic stem cells in adult hematopoiesis.

Authors:  Motoshi Ichikawa; Takashi Asai; Toshiki Saito; Sachiko Seo; Ieharu Yamazaki; Tetsuya Yamagata; Kinuko Mitani; Shigeru Chiba; Seishi Ogawa; Mineo Kurokawa; Hisamaru Hirai
Journal:  Nat Med       Date:  2004-02-15       Impact factor: 53.440

9.  AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis.

Authors:  T Okuda; J van Deursen; S W Hiebert; G Grosveld; J R Downing
Journal:  Cell       Date:  1996-01-26       Impact factor: 41.582

10.  The Runx1 transcription factor inhibits the differentiation of naive CD4+ T cells into the Th2 lineage by repressing GATA3 expression.

Authors:  Okiru Komine; Keitaro Hayashi; Waka Natsume; Toshio Watanabe; Youichi Seki; Noriyasu Seki; Ryoji Yagi; Wataru Sukzuki; Hidekazu Tamauchi; Katsuto Hozumi; Sonoko Habu; Masato Kubo; Masanobu Satake
Journal:  J Exp Med       Date:  2003-06-30       Impact factor: 14.307

View more
  18 in total

1.  The human SWI/SNF complex associates with RUNX1 to control transcription of hematopoietic target genes.

Authors:  Rachit Bakshi; Mohammad Q Hassan; Jitesh Pratap; Jane B Lian; Martin A Montecino; Andre J van Wijnen; Janet L Stein; Anthony N Imbalzano; Gary S Stein
Journal:  J Cell Physiol       Date:  2010-11       Impact factor: 6.384

2.  Regulation of postnatal forebrain amoeboid microglial cell proliferation and development by the transcription factor Runx1.

Authors:  Morena Zusso; Laurent Methot; Rita Lo; Andrew D Greenhalgh; Samuel David; Stefano Stifani
Journal:  J Neurosci       Date:  2012-08-15       Impact factor: 6.167

3.  PR-Set7 establishes a repressive trans-tail histone code that regulates differentiation.

Authors:  Jennifer K Sims; Judd C Rice
Journal:  Mol Cell Biol       Date:  2008-05-12       Impact factor: 4.272

Review 4.  Posttranslational modifications of RUNX1 as potential anticancer targets.

Authors:  S Goyama; G Huang; M Kurokawa; J C Mulloy
Journal:  Oncogene       Date:  2014-09-29       Impact factor: 9.867

5.  Nuclear FAK and Runx1 Cooperate to Regulate IGFBP3, Cell-Cycle Progression, and Tumor Growth.

Authors:  Marta Canel; Adam Byron; Andrew H Sims; Jessy Cartier; Hitesh Patel; Margaret C Frame; Valerie G Brunton; Bryan Serrels; Alan Serrels
Journal:  Cancer Res       Date:  2017-08-14       Impact factor: 12.701

Review 6.  Molecular mechanisms of leukemia-associated protein degradation.

Authors:  Ying-Li Wu; Hu-Chen Zhou; Guo-Qiang Chen
Journal:  Front Med China       Date:  2010-11-19

7.  MLL5 contributes to hematopoietic stem cell fitness and homeostasis.

Authors:  Yan Zhang; Jasmine Wong; Mark Klinger; Mary T Tran; Kevin M Shannon; Nigel Killeen
Journal:  Blood       Date:  2008-09-25       Impact factor: 22.113

8.  Activated Notch1 target genes during embryonic cell differentiation depend on the cellular context and include lineage determinants and inhibitors.

Authors:  Franziska Meier-Stiegen; Ralf Schwanbeck; Kristina Bernoth; Simone Martini; Thomas Hieronymus; David Ruau; Martin Zenke; Ursula Just
Journal:  PLoS One       Date:  2010-07-08       Impact factor: 3.240

9.  Expressional changes of genes and miRNA in common megakaryocyte-erythroid progenitors from lower-risk myelodysplastic syndrome.

Authors:  Kazuhiro Maki; Ko Sasaki; Yasunobu Nagata; Fusako Nagasawa; Yuka Nakamura; Seishi Ogawa; Kinuko Mitani
Journal:  Int J Hematol       Date:  2014-07-24       Impact factor: 2.490

10.  Sall4 overexpression blocks murine hematopoiesis in a dose-dependent manner.

Authors:  Samuel Milanovich; Jonathan Peterson; Jeremy Allred; Cary Stelloh; Kamalakannan Rajasekaran; Joseph Fisher; Stephen A Duncan; Subramaniam Malarkannan; Sridhar Rao
Journal:  Exp Hematol       Date:  2014-09-20       Impact factor: 3.084

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.